Shopping Cart
- Remove All
Your shopping cart is currently empty
TASP0390325
Catalog No. T28926Cas No. 1642187-96-9
Alias TASP-0390325, TASP 0390325
TASP0390325 is an orally active and high affinity arginine pressin receptor 1B (V1B receptor) antagonist that shows antidepressant and anxiolytic activity in animal studies and blocks V1B receptors in the anterior pituitary gland in vivo.
TASP0390325
Catalog No. T28926Alias TASP-0390325, TASP 0390325Cas No. 1642187-96-9
TASP0390325 is an orally active and high affinity arginine pressin receptor 1B (V1B receptor) antagonist that shows antidepressant and anxiolytic activity in animal studies and blocks V1B receptors in the anterior pituitary gland in vivo.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $52 | In Stock | |
| 5 mg | $123 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $455 | In Stock | |
| 50 mg | $787 | In Stock | |
| 100 mg | $1,280 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "TASP0390325"
Tolvaptan
OPC-41061
T2326150683-30-0
Tolvaptan (OPC-41061) is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
- $32
Size
QTY
Tolvaptan
OPC-41061
T2326150683-30-0
Tolvaptan (OPC-41061) is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
- $32
Size
QTY
Nelivaptan
SSR149415, SR-149415, SR 149415
T28153439687-69-1In house
Nelivaptan (SR 149415) is a vasopressin V1b receptor antagonist that can eliminate CHS-induced GE damage and inhibit [3H]AVP binding in a competitive manner.
- $71
Size
QTY
Fuscoside
OPC 21268
T4355131631-89-5
Fuscoside (OPC-21268) is a non-peptide arginine vasopressin (AVP) receptor VI antagonist with an IC50 value of 0.4 μM[2].
- $52
Size
QTY
OPC-51803
SOU-003, SOU003, SOU 003, OPC51803, OPC 51803
T28257192514-54-8In house
OPC-51803 is an orally available nonapeptidylpressor (AVP) V(2) receptor selective agonist for the treatment of urinary incontinence and nocturia.
- $350
Size
QTY
Felypressin acetate
PLV2. H-Cys-Phe-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Disulfide bond), PLV-2, PLV 2, 2-(L-Phenylalanine)-8-L-lysinevasopressin
T2568L914453-97-7
Felypressin acetate (PLV-2) is an agonist of vasopressin 1 and acts on all arginine vasopressin receptors 1AS. Felypressin acetate can be used in dental procedures.
- $39
Size
QTY
Felypressin acetate
PLV2. H-Cys-Phe-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Disulfide bond), PLV-2, PLV 2, 2-(L-Phenylalanine)-8-L-lysinevasopressin
T2568L914453-97-7
Felypressin acetate (PLV-2) is an agonist of vasopressin 1 and acts on all arginine vasopressin receptors 1AS. Felypressin acetate can be used in dental procedures.
- $39
Size
QTY
Atosiban acetate
RWJ22164, RW22164, Atosiban acetate (90779-69-4 free base)
T5148914453-95-5
Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
- $67
Size
QTY
Atosiban acetate
RWJ22164, RW22164, Atosiban acetate (90779-69-4 free base)
T5148914453-95-5
Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
- $67
Size
QTY
Atosiban acetate
RWJ22164, RW22164, Atosiban acetate (90779-69-4 free base)
T5148914453-95-5
Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
- $67
Size
QTY
Select Batch
Purity:98.62%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | TASP0390325 is an orally active and high affinity arginine pressin receptor 1B (V1B receptor) antagonist that shows antidepressant and anxiolytic activity in animal studies and blocks V1B receptors in the anterior pituitary gland in vivo. |
| In vivo | In male Sprague-Dawley (SD) rats weighing 211-246 g, oral administration of TASP0390325 (suspended in 0.5% methylcellulose 400) at doses of 0.3 and 1 mg/kg antagonized the increase in plasma ACTH levels induced by CRF/dDAVP at the dose of 1 mg/kg. In contrast, the doses of 0.3 and 1.0 mg/kg did not significantly affect basal ACTH levels[1]. |
| Alias | TASP-0390325, TASP 0390325 |
| Molecular Weight | 554.44 |
| Formula | C25H30Cl2FN5O4 |
| Cas No. | 1642187-96-9 |
Storage & Solubility Information
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (144.29 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy TASP0390325 | purchase TASP0390325 | TASP0390325 cost | order TASP0390325 | TASP0390325 chemical structure | TASP0390325 in vivo | TASP0390325 formula | TASP0390325 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.